” Colorectal Cancer : Preventing a Preventable Disease” was a program featured at the “Flint Community Cancer Screening and…
Colon Cancer
Heather Hampel, MS, City of Hope, Duarte, CA, discusses the benefits of performing germline genetic testing on all patients with…
NSPPD ( New Season Prophetic Prayers and Declaration) prayers is an online prayer platform that runs every Monday to Friday …
Viewer Discretion Advised! RIGHT LUNG LOBECTOMY NSCLC . 1 Of the treatments you get every 4-6 hr The frequency of visits …
Afsaneh Barzi, MD, PhD, City of Hope, Duarte, CA, describes strategies to reduce healthcare inequalities patients with colorectal cancer may face, including acknowledging these disparities, and cooperating with marginalized communities. Policies additionally need to reflect the fact that these patients are more likely to utilize the emergency room, as opposed to visiting a primary healthcare provider. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ
Red Meat Causes Colorectal Cancer?! | Monday Night Live w/ @Butterfueled
Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, comments on his highlights presented at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium, including findings from the SPOTLIGHT trial (NCT03504397) of zolbetuximab in gastric and gastroesophageal junction (GEJ) cancer, as well as the SUNLIGHT trial (NCT04737187) of trifluridine and tipiracil with bevacizumab in metastatic colorectal cancer. Additional highlights include the use of regorafenib as second-line therapy in gastric cancer. This interview took place at the ASCO 2023 GI Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Stacey Cohen, MD, Fred Hutchinson Cancer Center, Seattle, WA, comments on how genomic testing for molecular aberrations can influence treatment approaches in colorectal cancer. Liquid biopsies enable monitoring of multiple ctDNA mutations of varying frequencies, which can ultimately inform clinicians when a treatment regimen should be changed. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ
Heather Hampel, MS, City of Hope, Duarte, CA, comments on targeting and testing for BRCA1 and BRCA2 mutations in colorectal …
About Hi, friends welcome to the new video in this news we will talk about randy Gonzalez because randy Gonzalez died at the…
In 2022, 348 of the 469 names added to the International Association of Firefighters’ memorial wall were members who had died from occupational cancer.
Pele’s family spending Christmas in hospital after football legend’s cancer progressed